156 related articles for article (PubMed ID: 24900720)
1. Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.
Vignaroli G; Zamperini C; Dreassi E; Radi M; Angelucci A; Sanità P; Crespan E; Kissova M; Maga G; Schenone S; Musumeci F; Botta M
ACS Med Chem Lett; 2013 Jul; 4(7):622-6. PubMed ID: 24900720
[TBL] [Abstract][Full Text] [Related]
2. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-
Poggialini F; Vagaggini C; Brai A; Pasqualini C; Crespan E; Maga G; Perini C; Cabella N; Botta L; Musumeci F; Frosini M; Schenone S; Dreassi E
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839775
[TBL] [Abstract][Full Text] [Related]
3. Prodrugs of Pyrazolo[3,4-d]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model.
Vignaroli G; Iovenitti G; Zamperini C; Coniglio F; Calandro P; Molinari A; Fallacara AL; Sartucci A; Calgani A; Colecchia D; Mancini A; Festuccia C; Dreassi E; Valoti M; Musumeci F; Chiariello M; Angelucci A; Botta M; Schenone S
J Med Chem; 2017 Jul; 60(14):6305-6320. PubMed ID: 28650650
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.
Radi M; Dreassi E; Brullo C; Crespan E; Tintori C; Bernardo V; Valoti M; Zamperini C; Daigl H; Musumeci F; Carraro F; Naldini A; Filippi I; Maga G; Schenone S; Botta M
J Med Chem; 2011 Apr; 54(8):2610-26. PubMed ID: 21443205
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility.
Mahfouz NM; Hassan MA
J Pharm Pharmacol; 2001 Jun; 53(6):841-8. PubMed ID: 11428660
[TBL] [Abstract][Full Text] [Related]
6. Theoretical Studies on Pyrazolo[3,4-d]pyrimidine Derivatives as Potent Dual c-Src/Abl Inhibitors Using 3D-QSAR and Docking Approaches.
Zeng GH; Fang DQ; Wu WJ; Wang JP; Xie WG; Ma SJ; Wu JH; Shen Y
Mol Inform; 2014 Mar; 33(3):183-200. PubMed ID: 27485688
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
8. Modulating lipophilicity of rohitukine via prodrug approach: Preparation, characterization, and in vitro enzymatic hydrolysis in biorelevant media.
Kumar V; Bharate SS; Vishwakarma RA
Eur J Pharm Sci; 2016 Sep; 92():203-11. PubMed ID: 27422078
[TBL] [Abstract][Full Text] [Related]
9. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
10. Is prodrug design an approach to increase water solubility?
Sanches BMA; Ferreira EI
Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
[TBL] [Abstract][Full Text] [Related]
11. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
Vagaggini C; Petroni D; D'Agostino I; Poggialini F; Cavallini C; Cianciusi A; Salis A; D'Antona L; Francesconi V; Manetti F; Damonte G; Musumeci F; Menichetti L; Dreassi E; Carbone A; Schenone S
Drug Dev Res; 2024 Feb; 85(1):e22158. PubMed ID: 38349262
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: Preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line.
Fallacara AL; Mancini A; Zamperini C; Dreassi E; Marianelli S; Chiariello M; Pozzi G; Santoro F; Botta M; Schenone S
Bioorg Med Chem Lett; 2017 Jul; 27(14):3196-3200. PubMed ID: 28558969
[TBL] [Abstract][Full Text] [Related]
13. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-
Fallacara AL; Zamperini C; Podolski-Renić A; Dinić J; Stanković T; Stepanović M; Mancini A; Rango E; Iovenitti G; Molinari A; Bugli F; Sanguinetti M; Torelli R; Martini M; Maccari L; Valoti M; Dreassi E; Botta M; Pešić M; Schenone S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248184
[TBL] [Abstract][Full Text] [Related]
14. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
15. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
[TBL] [Abstract][Full Text] [Related]
16. Prodrugs of thiabendazole with increased water-solubility.
Nielsen LS; Bundgaard H; Falch E
Acta Pharm Nord; 1992; 4(1):43-9. PubMed ID: 1515051
[TBL] [Abstract][Full Text] [Related]
17. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
18. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
19. Strategies in the design of solution-stable, water-soluble prodrugs III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids.
Anderson BD; Conradi RA; Spilman CH; Forbes AD
J Pharm Sci; 1985 Apr; 74(4):382-7. PubMed ID: 3889274
[TBL] [Abstract][Full Text] [Related]
20. Prodrug study of plinabulin using a click strategy focused on the effects of a replaceable water-solubilizing moiety.
Yakushiji F; Tanaka H; Muguruma K; Iwahashi T; Yamazaki Y; Hayashi Y
Chem Pharm Bull (Tokyo); 2012; 60(7):877-81. PubMed ID: 22790821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
